CULLINAN MANAGEM. DL-,001

Cullinan Oncology's stock climbed to a 52-week high of $23.07, up 122% year-to-date and roughly 200% over the past year. Positive phase‑3 data from the REZILIENT3 study on zipalertinib plus chemotherapy and favorable FDA feedback on CLN‑049 boosted sentiment. UBS raised its price target to $27 with a “buy” rating, and William Blair confirmed “outperform.” However, InvestingPro notes a possible overvaluation relative to fair value. » More on de.investing.com

Cullinan Oncology’s stock rose to a new 52-week high of 19.43 USD and has a market capitalization of about 1.24 billion USD; the share price gained roughly 158% over the past year and about 77% year-to-date. InvestingPro currently rates the stock as overvalued. Cullinan reported positive feedback from the FDA on its T-cell engager CLN-049, paving the way for a potentially registration-enabling Phase 2 study in Q3 2026, and also released study data on CLN-978 and velinotamig; William Blair reiterated “Outperform” and Stifel maintains a “Buy” rating with a 28.00 USD price target. » More on de.investing.com

Cullinan Therapeutics’ stock rose 1.6% after positive end‑of‑Phase‑1 feedback from the FDA on CLN‑049, an FLT3xCD3 T‑cell engager for relapsed/refractory AML. The company plans to start a potentially approval‑enabling Phase‑2 study in Q3 2026, with a short dose‑optimization phase followed by a seamless transition into a single‑arm cohort. A dose‑escalation update is planned for Q4 2026; a Phase‑1/2 combination study with venetoclax and azacitidine is also planned. CLN‑049 has Orphan Drug status and FDA Fast Track designation. » More on de.investing.com